Literature DB >> 16616017

N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis.

Gjin Ndrepepa1, Siegmund Braun, Julinda Mehilli, Nicolas von Beckerath, Stephan Nekolla, Wolfgang Vogt, Markus Schwaiger, Albert Schömig, Adnan Kastrati.   

Abstract

We investigated whether N-terminal pro-brain natriuretic peptide (NT-pro-BNP) that was measured on admission in patients with acute myocardial infarction (AMI) predicts the efficacy of reperfusion or whether NT-pro-BNP provides prognostic information independent of infarct size as estimated by single-photon emission computed tomographic scintigraphy. The study included 174 patients with ST-segment elevation AMI who were admitted within 24 hours of pain onset. NT-pro-BNP level was measured on admission. Paired scintigraphic studies (before and 7 to 14 days after reperfusion) were performed to assess infarct size and define myocardial salvage. One-year clinical follow-up was assessed. Patients were categorized into the high NT-pro-BNP group (57 patients in the upper tertile of NT-pro-BNP) and low NT-pro-BNP group (117 patients in the middle and lower tertiles of NT-pro-BNP). Initial median perfusion defect was 35.0% (interquartile rage 20.0 to 53.0%) of the left ventricle in the high NT-pro-BNP group versus 19.0% (interquartile range 10.0 to 32.2) of the left ventricle in the low NT-pro-BNP group (p <0.001). Median salvage index was 0.36 (interquartile range 0.16 to 0.86) in the high NT-pro-BNP group versus 0.53 (interquartile range 0.31 to 0.75) in the low NT-pro-BNP group (p = 0.22). After adjustment in Cox's proportional hazards model, NT-pro-BNP remained an independent correlate of 1-year mortality (adjusted hazard ratio 2.31, 95% confidence interval 1.09 to 4.89, p = 0.03, high vs low NT-pro-BNP group). In conclusion, NT-pro-BNP measured on admission in patients with AMI correlates with scintigraphic area at risk and predicts prognosis but does not predict the efficacy of mechanical reperfusion by stenting or angioplasty.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616017     DOI: 10.1016/j.amjcard.2005.11.029

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.

Authors:  Jay S Shavadia; Christopher B Granger; Wendimagegn Alemayehu; Cynthia M Westerhout; Thomas J Povsic; Sean Van Diepen; Christopher Defilippi; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2020-06-17       Impact factor: 5.501

2.  Development and validation of a novel risk score to predict 5-year mortality in patients with acute myocardial infarction in China: a retrospective study.

Authors:  Yan Tang; Yuanyuan Bai; Yuanyuan Chen; Xuejing Sun; Yunmin Shi; Tian He; Mengqing Jiang; Yujie Wang; Mingxing Wu; Zhiliu Peng; Suzhen Liu; Weihong Jiang; Yao Lu; Hong Yuan; Jingjing Cai
Journal:  PeerJ       Date:  2022-01-04       Impact factor: 2.984

Review 3.  Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases.

Authors:  Hitoshi Nakagawa; Yoshihiko Saito
Journal:  Biology (Basel)       Date:  2022-07-06

4.  NT-proBNP Level Predicts Extent of Myonecrosis and Clinical Adverse Outcomes in Patients with ST-Elevation Myocardial Infarction: A Pilot Study.

Authors:  Mohammad Mathbout; Ahmed Asfour; Steve Leung; Georges Lolay; Amr Idris; Ahmed Abdel-Latif; Khaled M Ziada
Journal:  Med Res Arch       Date:  2020-02-21

5.  Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction.

Authors:  René P Andrié; Ulrich M Becher; Ricarda Frommold; Vedat Tiyerili; Jan W Schrickel; Georg Nickenig; Jörg O Schwab
Journal:  Crit Care       Date:  2012-08-13       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.